18 reports

Bladder Cancer 2017

7595 8658 6737

Bladder Cancer 2017 ##.

  • Bladder Cancer
  • Therapy
  • United States
  • Forecast

• Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?

  • Bladder Cancer
  • Therapy
  • Vaccine
  • United States
  • Supply

SIX PATIENTS (##. ##%) EXPERIENCED GRADE ≥## AES, INCLUDING POLLAKIURIA (N = ##), LYMPHOPENIA (N = ##), DYSURIA (N = ##), MICTURITION URGENCY (N = ##), AND NOCTURIA (N = ##).

  • Bladder Cancer
  • United States
  • Demand
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • CLINICAL TRIALS

The company reported one pharmaceuticals & healthcare deal each in 2016 and 2017.

  • Bladder Cancer
  • Israel
  • United States
  • Company
  • BioCancell Therapeutics, Inc.
  • CLINICAL TRIALS

The company reported one pharmaceuticals & healthcare deal each in 2016 and 2017.

  • Bladder Cancer
  • Israel
  • United States
  • Company
  • BioCancell Therapeutics, Inc.
  • LATEST CLINICAL TRIALS NEWS ON BLADDER CANCER
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Bladder Cancer
  • Cancer
  • Clinical Trial
  • United States
  • World
  • 5. All the trials included are unique trials.

Hoffmann-La Roche Ltd ## Feb 2018 ## Dec 2019 ## Programmed Cell Death ## Ligand ## (PD L## or B## Homolog ## or CD##) Inhibitor Programmed Cell Death ## Ligand ## (PD L## or B## Homolog ## or CD##) ##.

  • Bladder Cancer
  • Cell Therapy
  • Clinical Trial
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

## ## ## ## ## ## Japan ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## France ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## Italy Source: GlobalData' s Pharma Intelligence Center Clinical Tri

  • Bladder Cancer
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • Target
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Bladder Cancer
  • Cancer
  • World
  • Product Initiative
  • Merck & Co., Inc.
  • BLADDER CANCER - DORMANT PROJECTS, H1 2018 (CONTD..2), H1 2018
  • BLADDER CANCER - PIPELINE BY METAMAX LTD, H1 2018

Food and Drug Administration' s (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and Oncologic Drugs Advisory Committee (ODAC).

  • Bladder Cancer
  • Oncology
  • North America
  • United States
  • Product Initiative
  • BLADDER CANCER - PIPELINE BY TOLERO PHARMACEUTICALS INC
  • BLADDER CANCER - PIPELINE BY TOCAGEN INC

The company' s REIC expression technology (Reduced expression immortal cells) combines gene therapy, oncolytic viral vectors and immuno-oncology to kill cancer cells.

  • Bladder Cancer
  • Cancer
  • Pharmaceutical
  • Therapy
  • Product Initiative
  • DORMANT PROJECTS, H2 2016

THE MOLECULES DEVELOPED BY COMPANIES IN PHASE II, PHASE I, PRECLINICAL AND DISCOVERY STAGES ARE ##, ##, ## AND ## RESPECTIVELY.

  • Bladder Cancer
  • Hospital
  • Therapy
  • United States
  • World

The treatment, immuno-gene therapy, transfers just enough genetic material from an existing virus to trigger a patient' s innate defenses to destroy cancer cells.

  • Bladder Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Bladder Cancer
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative

Bladder Cancer: Disease and Pipeline Analysis Copyright and Usage Guidelines ## Table of Acronyms ## Chapter ## - Disease Overview ## Figure ##.

  • Bladder Cancer
  • Cancer
  • Pathology

Durvalumab acts as CD## (Programmed Cell Death ##-Ligand ## or PDL-##) inhibitor.

  • Bladder Cancer
  • Hepatitis
  • United States
  • Company Operations
  • Product Initiative

The treatment, immuno-gene therapy, transfers just enough genetic material from an existing virus to trigger a patient' s innate defenses to destroy cancer cells.

  • Bladder Cancer
  • Cancer
  • United States
  • Company Operations
  • Product Initiative

PHASE ##-## DOSE-ESCALATION STUDY OF VB-##, AN ANTI-ANGIOGENIC GENE THERAPY, AS MONOTHERAPY AND IN COMBINATION WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA.

  • Bladder Cancer
  • Oncology
  • Company
  • Demand
  • Product Initiative